Site-Specific Conjugation of Native Antibodies Using Engineered Microbial Transglutaminases-Reference-Cited by-同舟云学术

Site-Specific Conjugation of Native Antibodies Using Engineered Microbial Transglutaminases

Published:2020-03-05 Issue:4 Volume:31 Page:1070-1076
ISSN:1043-1802
Container-title:Bioconjugate Chemistry
language:en
Short-container-title:Bioconjugate Chem.

Author:

Dickgiesser Stephan¹^ORCID,Rieker Marcel¹²,Mueller-Pompalla Dirk¹,Schröter Christian¹,Tonillo Jason¹,Warszawski Shira³,Raab-Westphal Sabine¹,Kühn Stefanie¹,Knehans Tim¹,Könning Doreen¹,Dotterweich Julia¹,Betz Ulrich A. K.¹,Anderl Jan¹,Hecht Stefan¹,Rasche Nicolas¹

Affiliation:

1. Merck KGaA, Frankfurter Str. 250, 64293 Darmstadt, Germany

2. Clemens-Schöpf-Institut für Organische Chemie und Biochemie, Technische Universität Darmstadt, Alarich-Weiss-Str. 4, 64287 Darmstadt, Germany

3. Merck KGaA, 18 Hakishon, Yavne, 8122004 Israel

Publisher

American Chemical Society (ACS)

Subject

Organic Chemistry,Pharmaceutical Science,Pharmacology,Biomedical Engineering,Bioengineering,Biotechnology

Link

https://pubs.acs.org/doi/pdf/10.1021/acs.bioconjchem.0c00061

Reference43 articles.

1. EV-301: Phase III study to evaluate enfortumab vedotin (EV) versus chemotherapy in patients with previously treated locally advanced or metastatic urothelial cancer (la/mUC).